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Background: Recruiting cancer patients is a barrier often encountered in research trials. However, very few
randomized trials explore strategies to improve participation rates. The purpose of this study was to evaluate the
effectiveness of a pre-recruitment primer letter to recruit persons diagnosed with colorectal cancer for a research trial.
Methods: Potentially eligible participants were identified by the Victorian Cancer Registry. A total of 1,062 participants
were randomized to receive either a mailed explanatory primer letter designed to encourage research participation, or
no primer letter. Two weeks after the intervention, the Victorian Cancer Registry sought permission from patients to
release their contact details to researchers. Those who agreed were contacted and invited to the study.
Results: Pre-recruitment encouragement was not effective at increasing recruitment, with no significant differences
demonstrated between experimental groups. Overall, 40% (n = 425) consented to participate, 25% (n = 243) refused
and 35% (n = 394) did not respond.
Conclusions: While this study demonstrated disappointing outcomes, pre-recruitment letters should not be ruled out
as an approach altogether. Rather, future research should explore whether other factors to increase motivation, such as
intensity and timing, are feasible and acceptable for contacting cancer patients.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12609000628246
Keywords: Colorectal cancer, Patient recruitment, Population registers, Randomized controlled trialsBackground
Methodological importance of attaining high response rates
Producing high quality, generalizable data from research
trials is partly dependent on achieving high participation
rates [1]. Response or participation rates are a direct de-
terminant of whether the data accurately represent the
group of interest [1]. Accordingly, guidelines for report-
ing trials (e.g. CONSORT [2]) and tools for evaluating
the methodological quality of trials [3,4] emphasize the* Correspondence: chris.paul@newcastle.edu.au
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reproduction in any medium, provided the orimportance of high participation rates, with a high rate
often considered to be 60% or more [5]. In the case of tri-
als involving cancer patients, participation rates are often
below 60%, regardless of whether the trial involves med-
ical treatments [6], or supportive care [7]; or whether re-
cruitment is via clinics [8] or cancer registries [9].
Increasing participation of cancer patients in survey or
cross-sectional research studies
Research regarding survey participation has identified
incentives, personalization, reminders, and primer (pre-
notification) letters as potentially effective strategies for
enhancing response rates to research with varied po-
pulations [1,10]. The few studies trialing methods for
increasing survey response rates specifically among cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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trolled trial (RCT) of monetary incentives and survey length
produced no significant differences in survey response rates
for breast, prostate and colon cancer patients [11]. Modest
effects were found for incentives on survey response rates
for colorectal cancer (CRC) patients and their first degree
relatives (FDRs) [12], while another RCT found no effect
when comparing an enhanced letter to a standard invitation
letter in hematological cancer patients (response rate =
37%) [9]. The effectiveness of mailed reminders has been
demonstrated for head and neck cancer patients [13], with
reminders at two and four weeks increasing survey re-
sponse rates by 22% and 15% respectively to achieve an
overall response rate of 79.6%.
Testing the effectiveness of strategies to increase cancer
patient participation in trials
Despite the importance of achieving high trial participation
rates, very few RCTs focus on recruitment strategies relating
to cancer patients. A systematic review [14] assessing inter-
ventions for patient participation in cancer treatment trials
identified six studies, three of which were RCTs. None
found an increase in trial recruitment. Strategies involved
simplified documentation, a two-stage consent process, and
additional trial information [14]. Two subsequent RCTs
using audio-visual presentations found no effect among
breast [6], colorectal, or lung cancer patients [15]. A review
of 37 studies involving populations other than cancer pa-
tients found incentives, additional mailed contacts and in-
teractive recruitment approaches were effective [16]. The
larger pool of studies and positive findings among non-
cancer patients suggest it is worthwhile to continue to de-
velop and test such strategies for cancer-patient populations.
Incentives, while effective for some groups, are often not
appropriate for recruitment to treatment trials, while inter-
active options are not suitable for all settings. Therefore,
print-based approaches are worthy of further exploration.
Population-based cancer registries provide centralized
access to recruitment of cancer patients [17]. The use of
a primer letter is an appropriate, low-cost strategy and
may be beneficial where there is no personal contact,
such as recruitment via cancer registries.
This study aimed to examine whether a primer letter
compared to no primer letter, would improve research
participation in CRC patients selected from a cancer regis-
try. Given the importance of participant retention in trials,
the study also explored whether receipt of the primer was




This study was conducted as part of the baseline phase
of a larger RCT aiming to improve surveillance amongthose with CRC and improve appropriate screening
among their FDRs [18]. The trial involved persons regis-
tered with the Victorian Cancer Registry (VCR) as being
diagnosed with CRC. All diagnoses of cancer in Victoria
are notified to the VCR. The primer letter study involved
only the index cases.
Potentially eligible participants (18 years or older, a
primary diagnosis of CRC, and within 3 months of diag-
nosis) were randomized by the VCR, to receive either a
mailed primer letter (experimental group) or no primer
letter (control group). Randomization was performed by
using a randomized block design with the randomization
sequence generated using Proc Plan in SAS. Participant
eligibility criteria were based on the need of the larger
RCT to provide intervention to patients soon after initial
treatment. A process of rolling recruitment was used
until assignment of groups was complete. Allocation was
concealed to patients and researchers, with patient as-
signment revealed to researchers at conclusion of the
trial. Randomization occurred at the point of diagnosis
confirmation at the VCR. Simultaneously, a letter was
sent to each patient’s treating clinician regarding
whether the patient was well enough to participate in
the main trial and had sufficient fluency in English to
complete the study. The VCR adopts a passive approach
to recruitment, therefore, if clinicians did not respond,
the potential participant was considered eligible. Those
considered ineligible by their clinician were excluded.
Consent into the study was a two stage process. Firstly,
at approximately two weeks following the primer letter,
the VCR contacted eligible patients by mail for permis-
sion to release their contact details to the researchers.
Secondly, those who agreed to be contacted by re-
searchers, were invited to participate in the study by
mail, with two reminder letters sent to non-responders.
Written consent to participate in the main trial and
completion of the 12 month follow-up survey were used
as the primer letter study outcome measures. Figure 1
describes the recruitment process.
Human research ethics approval for both the main trial
and this study were obtained from The University of
Newcastle and The Cancer Council Victoria, and regis-
tered with the Australian and New Zealand Clinical Trials
Registry, registration number ACTRN12609000628246.
The primer letter
The primer letter (appendix 1), designed to encourage
research participation, was signed by the Director of the
Cancer Council Victoria (CCV), highlighting: i) the im-
portance of participation in research studies; ii) the role
the VCR plays in assisting recruitment to research studies;
and iii) the benefits to the individual and to the commu-
nity of research participation. The letter followed behav-
ioral principles for effective communication [19] including
Figure 1 Diagram of recruitment procedure. *‘Not included in trial’ are those that were outside 3 months of diagnosis and those who were
outside the trial period.
Table 1 Response rates to receive invitation in main trial









Primer letter 207 (40%) 131 (25%) 181 (35%) 519
Control 218 (40%) 112 (21%) 213 (39%) 543
Total 425 243 394 1,062
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structure and repetition of main points. The primer letter
required no response from participants and emphasized
participants’ right to choose whether or not to be involved
with research should they be invited to do so.
Statistical methods
The primary outcome of the study was to detect differences
in participation rates (i.e. consent for study invitation) be-
tween experimental groups. Patients were randomized until
a sample size of approximately 1,000 was obtained to pro-
vide 80% power, with a 5% significance level, to detect a dif-
ference of 9%. Additional eligible patients on the registry
were entered directly into the main trial. Consenting partic-
ipants were compared between experimental groups using
the chi-square test of independence.
Results and discussion
Of the 1,062 eligible patients, 425 (40%) provided consent
to make their details available to the researchers, 243 (25%)
refused, and 394 (35%) did not respond to the mailed invi-
tation. Persons more likely to consent to the trial were
under 70 years and born in Australia. There was no dif-
ference in disease characteristics between the groups.
As shown in Table 1, those receiving a primer letter
were not significantly more likely to consent compared
to persons not receiving a primer letter (χ2(2df ) = 3.83,
P = 0.147). Of those who consented, 296 (70%) com-
pleted the study baseline measure and 212 (50%) com-
pleted the 12 month follow-up measure. There was nosignificant difference between experimental groups in
completion of baseline or follow-up measures (χ2(1df )
< 1.6, P > 0.21).
The study findings indicated that pre-recruitment en-
couragement was not effective in increasing recruitment
to a subsequent trial relating to surveillance for people
diagnosed with CRC. This finding is in accord with the
few prior trials of recruitment-enhancing strategies for
trials with cancer patients [6,15].
The finding is, however, surprising given the success of
pre-notification strategies with non-cancer groups. Pre-
notification strategies have two primary elements. The
first relates to attention and preparation - raising the like-
lihood that an invitation to participate in a trial will be no-
ticed or considered given it has been heralded on a prior
occasion. The second element relates to raising motivation
via an appeal to altruism. One potential explanation for
the null finding is that these two potential effects are small
and short-lived (if they occur at all) in the case of cancer
patients. The invitation to participate may need to be very
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intensive to exert an effect over and above the psycho-
logical distress often associated with the diagnosis and
treatment of cancer. In this study, there was approxi-
mately two weeks between the primer letter and the invi-
tation to participate in the trial.
Previous studies exploring barriers to participation in
clinical cancer trials indicate patients prefer the freedom
to explore medical treatments outside of trials [20], and
may lack interest in trial participation [7]. Interest and
motivation appear to be the more modifiable factors,
and therefore, those most relevant to explore further. It
is possible that in this case, the research participation
letter was sent at a time when the study topic (improv-
ing disease surveillance among patients and screening in
their FDRs) was not considered a priority to patients, as
many may have been undergoing active treatment.
Conclusions
While this study does not provide an endorsement of the
pre-recruitment strategy, it is not sufficient to rule out the
approach. Rather, future research should explore whether
more intensive and timely approaches to increasing mo-
tivation are feasible and acceptable in the context of con-
tacting cancer patients. Pre-recruitment primer letters
may act as part of a persuasion strategy. The disappointing
results of this study may justify the exploration of tech-
niques such as testimonial references (e.g. ‘person like me’
endorsements) and compelling examples of the benefits in
research participation, in the interests of enhancing the
validity and generalizability of studies.
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